Search

KR-20260064975-A - Composite composition for improving blood flow and preventing or improving thrombosis comprising Artemisia Princeps Pamp.

KR20260064975AKR 20260064975 AKR20260064975 AKR 20260064975AKR-20260064975-A

Abstract

The present invention relates to a composition for various uses that includes lion's paw mugwort extract and green tea extract as active ingredients, has a blood circulation improving effect, and can prevent, improve, or treat cardiovascular disease or thrombosis.

Inventors

  • 한재갑
  • 박경숙
  • 고유진
  • 이정민
  • 이홍진

Assignees

  • 주식회사 시나몬랩

Dates

Publication Date
20260508
Application Date
20241030

Claims (20)

  1. A pharmaceutical composition for the prevention or treatment of cardiovascular disease, comprising lion's paw mugwort extract and green tea extract as active ingredients in a weight ratio of 2 to 10:1.
  2. In paragraph 1, A pharmaceutical composition comprising the above lion's paw mugwort extract and green tea extract in a weight ratio of 5 to 10:1.
  3. In paragraph 1, A pharmaceutical composition wherein the above lion's paw mugwort extract is obtained by a method comprising the steps of: extracting lion's paw mugwort by adding a mixed solvent of water and alcohol; filtering the lion's paw mugwort extract using a filter having a pore size of 0.1 to 30 μm; and concentrating the concentrate until the concentration reaches 10 to 100 brix.
  4. In paragraph 3, A pharmaceutical composition performed by adding dextrin, cyclodextrin, or a mixture thereof in an amount of 5 to 50 weight percent relative to the weight of Artemisia annua before or during the above-mentioned concentrating step.
  5. In paragraph 4, A pharmaceutical composition in which the above dextrin or cyclodextrin has a dextrose equivalent (DE) of 5 to 30.
  6. In paragraph 1, A pharmaceutical composition wherein the above green tea extract is obtained by a method comprising the steps of: adding an extraction solvent to green tea to extract it; filtering the green tea extract using a filter having a pore size of 0.1 to 30 μm; and concentrating the concentrate until the concentration reaches 10 to 100 brix.
  7. In paragraph 6, A pharmaceutical composition in which the extracted green tea is roasted at a temperature of 100 to 200 ℃ for 10 seconds to 10 minutes.
  8. In paragraph 1, A pharmaceutical composition in which the above lion's paw mugwort extract contains at least 1.2 mg/g of eupatilin and at least 0.24 mg/g of jaceosidin.
  9. In paragraph 1, A pharmaceutical composition wherein the green tea extract comprises 70 mg/g or more of epigallocatechin gallate ((-)-Epigallocatechin-gallate; EGCG) or 200 mg/g or more of catechin containing epigallocatechin gallate.
  10. In paragraph 1, A pharmaceutical composition wherein the above-mentioned cardiovascular disease is hypertension, angina pectoris, acute coronary syndrome, arteriosclerosis, atherosclerotic arteriosclerosis, carotid artery disease, cerebrovascular disease, congestive heart failure, congenital heart disease, coronary artery disease, dyslipidemia, vascular endothelial dysfunction, intermittent claudication, ischemia-reperfusion injury, ischemic heart disease, myocardial infarction, peripheral vascular disease, restenosis, or renal artery atherosclerosis or thrombosis.
  11. A food composition for the prevention or improvement of cardiovascular disease, comprising lion's paw mugwort extract and green tea extract as active ingredients in a weight ratio of 2 to 10:1.
  12. A food composition for improving blood circulation, comprising lion's paw mugwort extract and green tea extract as active ingredients in a weight ratio of 2 to 10:1.
  13. A pharmaceutical composition for the prevention or treatment of thrombosis, comprising lion's paw mugwort extract and green tea extract as active ingredients in a weight ratio of 5 to 10:1.
  14. A food composition for the prevention or improvement of thrombosis, comprising lion's paw mugwort extract and green tea extract as active ingredients in a weight ratio of 5 to 10:1.
  15. Step of preparing lion's paw mugwort extract; Step of preparing green tea extract; and The method includes the step of mixing the above lion's paw mugwort extract and green tea extract, A method for preparing a pharmaceutical composition for the prevention or treatment of cardiovascular disease, comprising the step of preparing the above lion's paw mugwort extract, the step of extracting lion's paw mugwort by adding a mixed solvent of water and alcohol; the step of filtering the lion's paw mugwort extract using a filter with a pore size of 0.1 to 30 μm; and the step of concentrating the concentrate until the concentration reaches 10 to 100 brix.
  16. In paragraph 15, A method of preparation in which, during the mixing step above, lion's paw mugwort extract and green tea extract are mixed in a weight ratio of 2 to 10:1.
  17. In Paragraph 16, A method for manufacturing the above green tea extract, comprising the steps of: adding an extraction solvent to green tea to extract it; filtering the green tea extract using a filter with a pore size of 0.1 to 30 μm; and concentrating the concentrate until the concentration reaches 10 to 100 brix.
  18. A pharmaceutical composition for the prevention or treatment of cardiovascular disease comprising eupatilin or a pharmaceutically acceptable salt thereof; jaceosidin or a pharmaceutically acceptable salt thereof; and catechin or a pharmaceutically acceptable salt thereof as active ingredients.
  19. In Paragraph 18, A pharmaceutical composition in which the above catechin comprises (-)-Epigallocatechin-gallate (EGCG).
  20. A food composition for the prevention or improvement of cardiovascular disease comprising eupatilin or a pharmaceutically acceptable salt thereof; jaceosidin or a pharmaceutically acceptable salt thereof; and catechin or a pharmaceutically acceptable salt thereof as active ingredients.

Description

Composite composition for improving blood flow and preventing or improving thrombosis comprising Artemisia princeps pamp. The present invention relates to a composition for various uses that has a blood circulation improving effect and can prevent, improve, or treat cardiovascular diseases such as thrombosis. Blood consists of arteries, capillaries, and veins, and transports oxygen, nutrients, hormones, cells, and other essential components through the vascular network. Vascular disease can be caused by impaired blood flow that hinders the proper delivery of blood to specific parts of the body. Vascular disease is a leading cause of death worldwide, and the early stage of vascular disease is endothelial dysfunction in humans (Balta S. Current Vascular Pharmacology. 19(3): 243-249 (2021)). Endothelial cells, which form the inner lining of blood vessels, play a crucial role in maintaining proper vascular function (Barakat AI. Comptes Rendus Physique. 14(6): 479-496 (2013)). Damage to endothelial cells caused by chronic inflammation and reactive oxygen species can lead to vascular endothelial dysfunction, which can induce thrombosis and atherosclerosis due to the expression of adhesion molecules and coagulation activity (Liao JK. J Clin Invest. 2013 Feb;123(2):540-1; Moris et al., Ann Transl Med. 2017 Aug;5(16):326). In particular, inflammation caused by external stimuli triggers the activation of platelets, leukocytes, and endothelial cells, and interactions between these cells lead to damage and dysfunction of endothelial cells (Aksu et al., 2012). Examining this signaling in terms of marker expression, NF-κB signaling acts as a central mediator of inflammation in the process of inflammation-induced thrombosis (Monaco and Paleolog, Cardiovascular Research. 61(4): 671-682 (2004)). Activation of NF-κB induces the expression of cell adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-Selectin, and P-Selectin in endothelial cells, causing inflammatory cells, including monocytes and neutrophils, to adhere to the blood vessel wall. Consequently, activation of the inflammatory signaling NF-κB in endothelial cells induces adhesion molecules that promote the binding and migration of leukocytes, thereby increasing the potential for leukocyte thrombus formation (Mussbacher et al., Frontiers in Immunology. 10 (2019); Sprague and Khalil, Biochemical Pharmacology. 78(6): 539-552 (2009)). In addition, nitric oxide (NO) synthesized by endothelial nitric oxide synthase (eNOS) is known to be involved in vasodilation by regulating vascular tone (Ahmad et al., International Journal of Molecular Sciences. 19(9) (2018); Kiani et al., J Prev Med Hyg. 63(2 Suppl 3): E239-E245 (2022); Levine et al., Cardiology. 122(1): 55-68 (2012)). Figure 1 shows a graph of the change in cell viability measured by MTT assay after treating vascular endothelial cells with the lion's paw mugwort extract according to the present invention at different concentrations in Experimental Example 1. Figure 2 shows a graph of the change in cell viability measured by MTT assay after treating vascular endothelial cells with green tea extract according to the present invention at different concentrations in Experimental Example 1. Figure 3 is a graph showing the results of confirming the change in the expression level of IκBα through Western blot after treating vascular endothelial cells in Experimental Example 2 with a mixture of lion's paw mugwort extract and green tea extract according to the present invention in various weight ratios, followed by treatment with the inflammatory cytokine TNF-α. Figure 4 is a graph showing the results of confirming the change in the expression level of ICAM-1 through Western blot after treating vascular endothelial cells in Experimental Example 3 with a mixture of lion's paw mugwort extract and green tea extract according to the present invention in various weight ratios, followed by treatment with the inflammatory cytokine TNF-α. Figure 5 is a graph showing the results of confirming the change in the expression level of p-eNOS through Western blot after treating vascular endothelial cells with a mixture of lion's paw mugwort extract and green tea extract according to the present invention in Experimental Example 4. Figure 6 shows a micrograph of THP-1 cells stained with Calcein-AM dye after co-culturing vascular endothelial cells and monocyte cells in Experimental Example 5, followed by sequential treatment with a mixture of Artemisia annua extract and green tea extract according to the present invention and the inflammatory cytokine TNF-α. Figure 7 is a graph showing the results of quantifying the average number of cells using Image-J software for the four zones observed with a microscope in Figure 6. Figure 8 is a graph showing the change in LFA-1 mRNA expression levels through qRT-PCR after co-culturing vascular endothelial cells and monocyte cells in Experim